atai Life Sciences is one of the world’s leading biopharmaceutical company incubating and accelerating the development of highly effective mental health treatments that address the unmet needs of patients. Our partnership will ensure that atai Life Sciences has a stable and secure supply of psychedelic compounds for use in scientific research regarding their benefits for human mental health and wellness.
Collaboration is the key.
Our synthetic genomics and bio-engineering expertise has significantly advanced our proprietary yeasts, enzymes, and production processes. Our high throughput Bio-Informatics platform seeks, filters, and discovers the unique and optimal enzymes from plants and other sources to domesticate for our novel production yeast strains. As a result, we can develop custom production process technologies to support and efficiently scale drug product manufacturing to meet clinical patient supply requirements’ demands and move swiftly through clinical development.
Our partnership program aims to align with innovative companies to discover, patent, and advance the research of some of the world’s most exciting compounds:
Keep reading for more on our current scientific partners, along with additional information about how we can help your company through a partnership with CB Therapeutics.
CB Therapeutics produces natural molecules and their analogs as therapeutic compounds for clinical research, and the commercial market. These naturally-produced molecules and their analogs with greater purity, consistency, and efficiency. After more than four years in research and development, we have focused on the therapeutic potential of cannabinoids and tryptamines for use in treating depression, PTSD, anxiety, addiction, and other mental disorders. As a result, we can produce these phytochemicals and other promising molecules and compounds more rapidly, utilizing fewer resources, at greater yields, and with more purity, consistency, and efficiency than Mother Nature.